[1]Sharma P, Sharma BC, Sarin SK.Predictors of nonresponse to lactulose in patients with cirrhosis and hepatic encephalopathy[J].Eur J Gastroenterol Hepatol, 2010, 22 (5) :526-531.
|
[2]Sharma P, Sharma BC, Sarin SK.Predictors of nonresponse to lactulose for minimal hepatic encephalopathy in patients with cirrhosis[J].Liver Int, 2009, 29 (9) :1365-1371.
|
[3]Prasad S, Dhiman RK, Duseja A, et al.Lactulose imp-roves cognitive functions and health-related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy[J].Hepatology, 2007, 45 (3) :549-559.
|
[4]Bass NM, Mullen KD, Sanyal A, et al.Rifaximin treatment in hepatic encephalopathy[J].N Engl J Med, 2010, 362 (12) :1071-1081.
|
[5]Basu P, Rayapudi K, Estevez J, et al.A pilot study utilizing nitazoxanide for hepatic encephalopathy in chronic liver failure[R].San Francisco, CA:Program and abstracts of the 59th Annual Meeting of the American Association for the Study of Liver Diseases, 2008, 1742.
|
[6]Malaguarnera M, Gargante MP, Malaguarnera G, et al.Bifidobacterium combined with fructo-oligosaccharide versus lactulose in the treatment of patients with hepatic encephalo-pathy[J].Eur J Gastroenterol Hepatol, 2010, 22 (2) :199-206.
|
[7]Schmid M, Peck-Radosavljevic M, Konig F, et al.A double-blind, randomized, placebo-controlled trial of intravenous L-ornithine-L-aspartate on postural control in patients with cirrhosis[J].Liver Int, 2010, 30 (4) :574-582.
|
[8]Soárez PC, Oliveira AC, Padovan J.A critical analysis of studies assessing L-ornithine-L-aspartate (LOLA) in hepatic encephalopathy treatment[J].Arq Gastroenterol, 2009, 46 (3) :241-247.
|
[9]Jalan R, Wright G, Davies NA, et al.L-Ornithine phenylacet-ate (OP) :a novel treatment for hyperammonemia and hepatic encephalopathy[J].Med Hypotheses, 2007, 69 (5) :1064-1069.
|
[10]Al Sibae MR, McGuire BM.Current trends in the treatment of hepatic encephalopathy[J].Therapeutics and Clinical Risk Manag-ement, 2009, 5 (3) :617-626.
|
[11]Malaguarnera M, Gargante MP, Cristaldi E, et al.Acetyl-L-carnitine treatment in minimal hepatic encephalopathy[J].Dig Dis Sci, 2008, 53 (11) :3018-3025.
|
[12]Abdel-Hady H, Zaki A, Badra G, et al.Helicobacter pyl-ori infection in hepatic encephalopathy:Relationship to plasma endotoxins and blood ammonia[J].Hepatol Res, 2007, 37 (12) :1026-1033.
|
[13]Als-Nielsen B, Gluud LL, Gluud C.Benzodiazepine receptor antagonists for hepatic encephalopathy[J].Cochrane Database Syst Rev, 2004, 34 (2) :2798-2803.
|
[14]Hamed SA, Hamed EA, Farghaly MH, et al.Trace elements and flapping tremors in patients with liver cirrhosis.Is there a relationship[J].Saudi Med J, 2008, 29 (3) :345-351.
|
[15]Katayama K.Ammonia metabolism and hepatic ence-phalo-pathy[J].Hepatol Res, 2004, 30 (2) :73-79.
|
[16]秦万龙, 张静, 李伦, 等.纳洛酮对肝性脑病疗效的系统评价[J].兰州大学学报, 2009, 35 (3) :55-63.
|
[17]欧阳伟.人工肝血浆置换治疗肝性脑病的临床观察[J].临床军医杂志, 2007, 35 (6) :852-854.
|
[18]周生明, 刘伟.人工肝血液灌流治疗重型肝炎合并肝性脑病疗效观察[J].中国血液净化, 2005, 4 (6) :339-340.
|
[19]王海艳, 李红伟, 毛敬珍.连续性血液滤过治疗重型肝炎合并肝性脑病16例临床疗效观察[J].临床肝胆病杂志, 2009, 25 (5) :364-365.
|
[20]Wang MM, Chen SJ, Ye QF, et al.Liver support therapy with molecular adsorbents recirculating system in liver failure:a summary of 252 cases from 14 centers in China[J].Chin Med J (Engl) , 2008, 121 (21) :2197-2201.
|
[21]Koivusalo AM, Kantola T, Arola J, et al.Is it possible to gain extra waiting time to liver transplantation in acute liver failure patients using albumin dialysis[J].Ther Apher Dial, 2009, 13 (5) :413-418.
|
[22]Khan AA, Shaik MV, Parveen N, et al.Human fetal liver derived stem cell transplantation as supportive modality in the management of end stage decompensated liver cirrhosis[J].Cell Transplant, 2010, 19 (4) :409-418.
|
[23]Tang XN, Yenari MA.Hypothermia as a cytoprotective strategy in ischemic tissue injury[J].Ageing Res Rev, 2010, 9 (1) :61-68.
|